Back to Search
Start Over
Monocytes reprogrammed by tumor microparticle vaccine inhibit tumorigenesis and tumor development.
- Source :
-
Cancer Nanotechnology (1868-6958) . 4/17/2023, Vol. 14 Issue 1, p1-20. 20p. - Publication Year :
- 2023
-
Abstract
- Tumor microparticles (T-MPs) are considered as a tumor vaccine candidate. Although some studies have analyzed the mechanism of T-MPs as tumor vaccine, we still lack understanding of how T-MPs stimulate a strong anti-tumor immune response. Here, we show that T-MPs induce macrophages to release a key chemotactic factor CCL2, which attracts monocytes to the vaccine injection site and enhances endocytosis of antigen. Monocytes subsequently enter the draining lymph node, and differentiate into monocyte-derived DCs (moDCs), which present tumor antigens to T lymphocytes and deliver a potent anti-tumor immune response. Mechanically, T-MPs activate the cGAS-STING signaling through DNA fragments, and then induce monocytes to upregulate the expression of IRF4, which is a key factor for monocyte differentiation into moDCs. More importantly, monocytes that have endocytosed T-MPs acquire the ability to treat tumors. Collectively, this work might provide novel vaccination strategy for the development of tumor vaccines and facilitate the application of T-MPs for clinic oncotherapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 18686958
- Volume :
- 14
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Cancer Nanotechnology (1868-6958)
- Publication Type :
- Academic Journal
- Accession number :
- 163149714
- Full Text :
- https://doi.org/10.1186/s12645-023-00190-x